7 completed. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 3 | Completed 3 |
Follow NHL: new trials by email Literature Review of NHL trials Research Report on NHL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL FT596, Rituximab - NHL, Non Hodgkin Lymphoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 7 | 2020-09-22 | 2024-07-09 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL | Phase 1 | Completed | Acerta Pharma BV | 30 | 2018-06-19 | 2022-08-15 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies CD22-CAR - NHL, Large Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 134 | 2014-12-12 | 2026-04-28 |
| Umbilical Cord Blood Transplant for Hematological Malignancies Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm - CML, AML | Phase 1 | Completed | University of Pennsylvania | 5 | 2009-01-01 | 2016-08-19 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
| Safety Study of NHL With 90Y-hLL2 IgG 90Y-hLL2 - NHL, B-cell NHL | Phase 1 / Phase 2 | Completed | Gilead Sciences | 59 | 2002-08-01 | 2021-08-16 |
Lymphoma, Non-Hodgkin (5) · Lymphoma (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Hematologic Diseases (4) · Lymphoma (4) · Lymphoma, B-Cell (3) · Histiocytic Disorders, Malignant (2) · Histiocytosis (2) · Leukemia, Lymphoid (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
Rituximab (2) · AZD5153 (1) · Biopsy (1) · Echocardiography (1) · Electrocardiography (1) · MZ1 compound (1) · Magnetic Resonance Imaging (1) · Positron-Emission Tomography (1) · Prednisone (1) · acalabrutinib (1) · ceralasertib (1) · danvatirsen (1) · epratuzumab (1) · magrolimab (1) · veltuzumab (1)
Gilead Sciences (2) · National Cancer Institute (NCI) (2) · Acerta Pharma BV (1) · Masonic Cancer Center, University of Minnesota (1) · University of Pennsylvania (1)
United States (6) · France (1) · Germany (1) · United Kingdom (1)
Christopher J Melani, M.D. (1) · David Porter, MD (1) · Dr.Veronika Bachanova, MD, PhD (1) · Elizabeth Hexner, MD (1) · Ian Flinn, MD, PhD (1) · Nirali N Shah, M.D. (1) · William A Wegener, MD, PhD (1) · William Wegener, MD, PhD (1)
PMID 21173095, PMID 26389849, PMID 26858124, PMID 32286905, PMID 34309174, PMID 34687939, PMID 37295816, PMID 37486616, PMID 37882668, PMID 41411486
2017 (1), P01CA111412 (1)